BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 29884612)

  • 1. Subtypes of Barrett's oesophagus and oesophageal adenocarcinoma based on genome-wide methylation analysis.
    Yu M; Maden SK; Stachler M; Kaz AM; Ayers J; Guo Y; Carter KT; Willbanks A; Heinzerling TJ; O'Leary RM; Xu X; Bass A; Chandar AK; Chak A; Elliott R; Willis JE; Markowitz SD; Grady WM
    Gut; 2019 Mar; 68(3):389-399. PubMed ID: 29884612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypomethylation of noncoding DNA regions and overexpression of the long noncoding RNA, AFAP1-AS1, in Barrett's esophagus and esophageal adenocarcinoma.
    Wu W; Bhagat TD; Yang X; Song JH; Cheng Y; Agarwal R; Abraham JM; Ibrahim S; Bartenstein M; Hussain Z; Suzuki M; Yu Y; Chen W; Eng C; Greally J; Verma A; Meltzer SJ
    Gastroenterology; 2013 May; 144(5):956-966.e4. PubMed ID: 23333711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alterations of the Wnt signaling pathway during the neoplastic progression of Barrett's esophagus.
    Clément G; Braunschweig R; Pasquier N; Bosman FT; Benhattar J
    Oncogene; 2006 May; 25(21):3084-92. PubMed ID: 16407829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypermethylation of the AKAP12 promoter is a biomarker of Barrett's-associated esophageal neoplastic progression.
    Jin Z; Hamilton JP; Yang J; Mori Y; Olaru A; Sato F; Ito T; Kan T; Cheng Y; Paun B; David S; Beer DG; Agarwal R; Abraham JM; Meltzer SJ
    Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):111-7. PubMed ID: 18199717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic alteration of the Wnt inhibitory factor-1 promoter occurs early in the carcinogenesis of Barrett's esophagus.
    Clément G; Guilleret I; He B; Yagui-Beltrán A; Lin YC; You L; Xu Z; Shi Y; Okamoto J; Benhattar J; Jablons D
    Cancer Sci; 2008 Jan; 99(1):46-53. PubMed ID: 18005197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Temporal evolution in caveolin 1 methylation levels during human esophageal carcinogenesis.
    Jin Z; Wang L; Cao Z; Cheng Y; Gao Y; Feng X; Chen S; Yu H; Wu W; Zhao Z; Dong M; Zhang X; Liu J; Fan X; Mori Y; Meltzer SJ
    BMC Cancer; 2014 May; 14():345. PubMed ID: 24885118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk.
    Schulmann K; Sterian A; Berki A; Yin J; Sato F; Xu Y; Olaru A; Wang S; Mori Y; Deacu E; Hamilton J; Kan T; Krasna MJ; Beer DG; Pepe MS; Abraham JM; Feng Z; Schmiegel W; Greenwald BD; Meltzer SJ
    Oncogene; 2005 Jun; 24(25):4138-48. PubMed ID: 15824739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genome-wide methylation analysis shows similar patterns in Barrett's esophagus and esophageal adenocarcinoma.
    Xu E; Gu J; Hawk ET; Wang KK; Lai M; Huang M; Ajani J; Wu X
    Carcinogenesis; 2013 Dec; 34(12):2750-6. PubMed ID: 23996928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma.
    Eads CA; Lord RV; Kurumboor SK; Wickramasinghe K; Skinner ML; Long TI; Peters JH; DeMeester TR; Danenberg KD; Danenberg PV; Laird PW; Skinner KA
    Cancer Res; 2000 Sep; 60(18):5021-6. PubMed ID: 11016622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aberrant methylation of secreted frizzled-related protein genes in esophageal adenocarcinoma and Barrett's esophagus.
    Zou H; Molina JR; Harrington JJ; Osborn NK; Klatt KK; Romero Y; Burgart LJ; Ahlquist DA
    Int J Cancer; 2005 Sep; 116(4):584-91. PubMed ID: 15825175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aberrantly methylated PKP1 in the progression of Barrett's esophagus to esophageal adenocarcinoma.
    Kaz AM; Luo Y; Dzieciatkowski S; Chak A; Willis JE; Upton MP; Leidner RS; Grady WM
    Genes Chromosomes Cancer; 2012 Apr; 51(4):384-93. PubMed ID: 22170739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Similarity of aberrant DNA methylation in Barrett's esophagus and esophageal adenocarcinoma.
    Smith E; De Young NJ; Pavey SJ; Hayward NK; Nancarrow DJ; Whiteman DC; Smithers BM; Ruszkiewicz AR; Clouston AD; Gotley DC; Devitt PG; Jamieson GG; Drew PA
    Mol Cancer; 2008 Oct; 7():75. PubMed ID: 18831746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Global DNA methylation patterns in Barrett's esophagus, dysplastic Barrett's, and esophageal adenocarcinoma are associated with BMI, gender, and tobacco use.
    Kaz AM; Wong CJ; Varadan V; Willis JE; Chak A; Grady WM
    Clin Epigenetics; 2016; 8():111. PubMed ID: 27795744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA methylation profiling in Barrett's esophagus and esophageal adenocarcinoma reveals unique methylation signatures and molecular subclasses.
    Kaz AM; Wong CJ; Luo Y; Virgin JB; Washington MK; Willis JE; Leidner RS; Chak A; Grady WM
    Epigenetics; 2011 Dec; 6(12):1403-12. PubMed ID: 22139570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequent methylation of eyes absent 4 gene in Barrett's esophagus and esophageal adenocarcinoma.
    Zou H; Osborn NK; Harrington JJ; Klatt KK; Molina JR; Burgart LJ; Ahlquist DA
    Cancer Epidemiol Biomarkers Prev; 2005 Apr; 14(4):830-4. PubMed ID: 15824152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Next-generation sequencing of endoscopic biopsies identifies ARID1A as a tumor-suppressor gene in Barrett's esophagus.
    Streppel MM; Lata S; DelaBastide M; Montgomery EA; Wang JS; Canto MI; Macgregor-Das AM; Pai S; Morsink FH; Offerhaus GJ; Antoniou E; Maitra A; McCombie WR
    Oncogene; 2014 Jan; 33(3):347-57. PubMed ID: 23318448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene expression profiling reveals stromal genes expressed in common between Barrett's esophagus and adenocarcinoma.
    Hao Y; Triadafilopoulos G; Sahbaie P; Young HS; Omary MB; Lowe AW
    Gastroenterology; 2006 Sep; 131(3):925-33. PubMed ID: 16952561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cellular origins and molecular mechanisms of Barrett's esophagus and esophageal adenocarcinoma.
    Fang Y; Chen X; Bajpai M; Verma A; Das KM; Souza RF; Garman KS; Donohoe CL; O'Farrell NJ; Reynolds JV; Dvorak K
    Ann N Y Acad Sci; 2013 Oct; 1300():187-199. PubMed ID: 24117642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impaired transforming growth factor beta signalling in Barrett's carcinogenesis due to frequent SMAD4 inactivation.
    Onwuegbusi BA; Aitchison A; Chin SF; Kranjac T; Mills I; Huang Y; Lao-Sirieix P; Caldas C; Fitzgerald RC
    Gut; 2006 Jun; 55(6):764-74. PubMed ID: 16368780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA methylation as an adjunct to histopathology to detect prevalent, inconspicuous dysplasia and early-stage neoplasia in Barrett's esophagus.
    Alvi MA; Liu X; O'Donovan M; Newton R; Wernisch L; Shannon NB; Shariff K; di Pietro M; Bergman JJ; Ragunath K; Fitzgerald RC
    Clin Cancer Res; 2013 Feb; 19(4):878-88. PubMed ID: 23243219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.